24 results
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
23 Apr 20
Avenue Therapeutics Announces Presentation of IV Tramadol E-Posters
9:00am
intensity differences through 24 hours post first dose). The key secondary endpoints included SPID48 (sum of pain intensity differences through 48 hours post
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
25 May 18
Regulation FD Disclosure
8:30am
) 360 Patients Placebo (n=135) IV tramadol 50 mg (n=135) Morphine (n=90) PRIMARY ENDPOINT Sum of Pain Intensity Differences (SPID) through 48 hours … post first dose PRIMARY ENDPOINT Sum of Pain Intensity Differences (SPID) through 24 hours post first dose Safety Study (n=250)
P=0.005 for the primary
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
21 May 18
Avenue Therapeutics Announces Positive Topline Phase 3 Data for Intravenous Tramadol in the Management of Postoperative Pain
8:15am
tramadol achieved the primary endpoint of a statistically significant improvement in Sum of Pain Intensity Difference over 48 hours (SPID48) compared … ) compared to placebo. The 50 mg arm also met all three key secondary endpoints (p < 0.01). The profile of pain intensity over time demonstrated that IV
8-K
ATXI
Avenue Therapeutics Inc
3 Jun 19
Avenue Therapeutics Announces Positive Topline Data from Second Pivotal Phase 3 Study of Intravenous Tramadol in the Management of Postoperative Pain
8:45am
trial of IV tramadol achieved the primary endpoint of a statistically significant improvement in Sum of Pain Intensity Difference over 24 hours (SPID24
8-K
ATXI
Avenue Therapeutics Inc
21 May 18
Avenue Therapeutics Announces Positive Topline Phase 3 Data for Intravenous Tramadol in the Management of Postoperative Pain
8:15am
the primary endpoint of a statistically significant improvement in Sum of Pain Intensity Difference over 48 hours (SPID48) compared to placebo in patients
FWP
6x9fx4 yo153wtuqtvrc
3 Oct 23
Free writing prospectus
5:47pm
FWP
mz0se6vqhb
5 Oct 23
Free writing prospectus
5:05pm
8-K
EX-99.1
c91v92804gb kza2u0
14 Aug 19
Avenue Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights
12:00am
8-K
EX-99.1
rorn8hqk
3 Jun 19
Avenue Therapeutics Announces Positive Topline Data from Second Pivotal Phase 3 Study of Intravenous Tramadol in the Management of Postoperative Pain
8:45am
8-K
EX-99.1
t9q4dj6ar
30 Mar 20
Avenue Therapeutics Reports Full Year 2019 Financial Results and Recent Corporate Highlights
9:01am
8-K
EX-99.1
5it2k9e4
12 Mar 19
Avenue Therapeutics Reports Full Year 2018 Financial Results and Recent Corporate Highlights
9:16am
10-12G/A
gz2suhzk31r0orwkrdjv
13 Mar 17
Registration of securities (amended)
12:00am
10-K
zy8icx
1 Mar 18
Annual report
12:00am
10-12G/A
oxt z5vw7rsvvz
6 Mar 17
Registration of securities (amended)
12:00am